ASCO® 2023

Enfortumab Vedotin | Urothelial Cancer | Abstract #4568

Enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin-ineligible patients (pts) with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data

Enfortumab Vedotin | Bladder Cancer | Abstract #4595

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H

Enfortumab Vedotin | Bladder Cancer | Abstract #4596

A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104)

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS4601

KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)

Enfortumab Vedotin | Head and Neck Cancer | Abstract #6017

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202